Research Paper

Pharmaceutical Research

, Volume 25, Issue 5, pp 1100-1109

First online:

The USP Performance Verification Test, Part I: USP Lot P Prednisone Tablets—Quality Attributes and Experimental Variables Contributing to Dissolution Variance

  • Gang DengAffiliated withUnited States Pharmacopeia
  • , Alyssa J. AshleyAffiliated withUnited States Pharmacopeia
  • , William E. BrownAffiliated withUnited States Pharmacopeia
  • , Joseph W. EatonAffiliated withUnited States Pharmacopeia
  • , Walter W. HauckAffiliated withUnited States Pharmacopeia
  • , Loice C. KikwaiAffiliated withUnited States Pharmacopeia
  • , Mark R. LiddellAffiliated withUnited States Pharmacopeia
  • , Ronald G. ManningAffiliated withDepartment of Health and Human Services
  • , Jimmy M. MunozAffiliated withUnited States Pharmacopeia
    • , Pallavi NithyanandanAffiliated withUnited States Pharmacopeia
    • , Maria J. GlasgowAffiliated withUnited States Pharmacopeia
    • , Erika StipplerAffiliated withUS Pharmacopeia, Department of Reference Materials Development
    • , Samir Z. WahabAffiliated withUnited States Pharmacopeia
    • , Roger L. WilliamsAffiliated withUnited States Pharmacopeia Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access



Beyond instrumental qualification, proficiency testing is not usually a prerequisite for many analytical procedures, given reliance on a manufacturer’s assay validation coupled with regulatory review and inspection. Given the special features of the dissolution procedure, proficiency testing was put in place initially by pharmaceutical manufacturers and carried on by USP. Proficiency testing is designed to help ensure that execution of a dissolution procedure for solid oral dosage forms adequately supports administrative and legal decisions so that measurements made at different times, by different analysts, or with different methods can be confidently compared. USP has applied metrological principles to aid practitioners in carrying out the dissolution procedure alone and in collaborative studies to facilitate understanding potential sources of variability.

Materials and Methods

The present study aimed to identify key dissolution variables associated with USP Lot P Prednisone Tablets in conjunction with the USP Performance Verification Test (PVT). Using five dissolution test assemblies from different manufacturers, at least four of six analysts determined percents prednisone dissolved on dissolution Apparatus 1 (basket) and Apparatus 2 (paddle) on each assembly. Six replicate experiments were performed on each analyst–assembly combination with a set of six to eight tablets in each experiment.

Results and Conclusions

Statistical analysis demonstrated that dissolution test assemblies were the largest factor contributing to dissolution variability. Inherent tablet variability was low, and USP Lot P Prednisone Tablets did not contribute importantly to dissolution variability. Contributions from analyst and analytical procedure also were estimated to be low.

Key words

dissolution performance verification performance verification test quality assurance United States Pharmacopeia